Mathew GG. Molecular markers or clinical end points? What is the optimal monitoring tool for low-dose rituximab in membranous nephropathy in resource-limited settings? J Nephrol 2025 Apr 7. doi: 10.1007/s40620-025-02273.
PMID: 40193044